CL2012000535A1 - Compuestos derivados de benzo[f][1,7]-naftiridina; moduladores de la actividad del receptor tipo-toll 8 (tlr); composicion farmaceutica; utiles para el tratamiento del asma, enfermedad pulmonar obstructiva cronica (copd), sindrome respiratorio de adultos (ards), colitis ulcerosa, enfermedad de crohn, entre otras. - Google Patents
Compuestos derivados de benzo[f][1,7]-naftiridina; moduladores de la actividad del receptor tipo-toll 8 (tlr); composicion farmaceutica; utiles para el tratamiento del asma, enfermedad pulmonar obstructiva cronica (copd), sindrome respiratorio de adultos (ards), colitis ulcerosa, enfermedad de crohn, entre otras.Info
- Publication number
- CL2012000535A1 CL2012000535A1 CL2012000535A CL2012000535A CL2012000535A1 CL 2012000535 A1 CL2012000535 A1 CL 2012000535A1 CL 2012000535 A CL2012000535 A CL 2012000535A CL 2012000535 A CL2012000535 A CL 2012000535A CL 2012000535 A1 CL2012000535 A1 CL 2012000535A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- naphthyridine
- benzo
- pharmaceutical composition
- treatment
- Prior art date
Links
- YESZJRASHAAFQD-UHFFFAOYSA-N benzo[f][1,7]naphthyridine Chemical compound C1=CC=C2C3=CC=CC=C3N=CC2=N1 YESZJRASHAAFQD-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title 1
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 208000011231 Crohn disease Diseases 0.000 title 1
- 102000008208 Toll-Like Receptor 8 Human genes 0.000 title 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23921709P | 2009-09-02 | 2009-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000535A1 true CL2012000535A1 (es) | 2012-08-17 |
Family
ID=43625759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000535A CL2012000535A1 (es) | 2009-09-02 | 2012-02-29 | Compuestos derivados de benzo[f][1,7]-naftiridina; moduladores de la actividad del receptor tipo-toll 8 (tlr); composicion farmaceutica; utiles para el tratamiento del asma, enfermedad pulmonar obstructiva cronica (copd), sindrome respiratorio de adultos (ards), colitis ulcerosa, enfermedad de crohn, entre otras. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9045470B2 (enExample) |
| EP (1) | EP2473508B1 (enExample) |
| JP (1) | JP5525614B2 (enExample) |
| CN (1) | CN102712636B (enExample) |
| AR (1) | AR078153A1 (enExample) |
| AU (1) | AU2010308524B2 (enExample) |
| BR (1) | BR112012004696B8 (enExample) |
| CA (1) | CA2772657C (enExample) |
| CL (1) | CL2012000535A1 (enExample) |
| CY (1) | CY1119618T1 (enExample) |
| DK (1) | DK2473508T3 (enExample) |
| EA (1) | EA020962B1 (enExample) |
| ES (1) | ES2627669T3 (enExample) |
| HR (1) | HRP20170707T1 (enExample) |
| HU (1) | HUE032323T2 (enExample) |
| IN (1) | IN2012DN02736A (enExample) |
| JO (1) | JO3257B1 (enExample) |
| LT (1) | LT2473508T (enExample) |
| MX (1) | MX2012002654A (enExample) |
| PE (1) | PE20121156A1 (enExample) |
| PL (1) | PL2473508T3 (enExample) |
| PT (1) | PT2473508T (enExample) |
| SI (1) | SI2473508T1 (enExample) |
| SM (1) | SMT201700276T1 (enExample) |
| TW (1) | TWI445708B (enExample) |
| UY (1) | UY32874A (enExample) |
| WO (1) | WO2011049677A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
| WO2012125942A1 (en) * | 2011-03-16 | 2012-09-20 | University Of Medicine And Dentistry Of New Jersey | Combination therapy with leukotoxin |
| US10149889B2 (en) | 2005-11-25 | 2018-12-11 | Rutgers, The State University Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
| EA021377B9 (ru) | 2008-12-09 | 2015-09-30 | Джилид Сайэнс, Инк. | Модуляторы толл-подобных рецепторов |
| EA026401B1 (ru) | 2009-09-02 | 2017-04-28 | Новартис Аг | Иммуногенные композиции, содержащие модуляторы активности tlr |
| CA2784580A1 (en) | 2009-12-15 | 2011-07-14 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| EP2402028A1 (en) * | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing and treating type 1 diabetes (II) |
| PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
| SI3970742T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za dostavo RNA, ki kodira imunogen |
| ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| BR112013008700B8 (pt) | 2010-10-11 | 2022-10-04 | Novartis Ag | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante |
| BR112013022397A2 (pt) | 2011-03-02 | 2017-09-26 | Derek OHagan | vacinas combinadas com doses menores de antígeno e/ou adjuvante |
| US8900626B2 (en) * | 2011-06-20 | 2014-12-02 | Senju Usa, Inc. | Transdermal drug delivery system and method of using the same |
| US11896636B2 (en) * | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| WO2013030378A1 (en) * | 2011-09-01 | 2013-03-07 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| CA2866426A1 (en) * | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
| RU2014140336A (ru) * | 2012-03-07 | 2016-04-27 | Новартис Аг | Иммунологически полезные соли аргинина |
| RU2014140521A (ru) * | 2012-03-08 | 2016-04-27 | Новартис Аг | Адъювантные составы бустерных вакцин |
| EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| CA2875391A1 (en) | 2012-07-27 | 2014-01-30 | Institut National De La Sante Et De La Recherche Medicale | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| EP2890387A1 (en) * | 2012-08-31 | 2015-07-08 | Novartis AG | Stabilised proteins for immunising against staphylococcus aureus |
| EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
| CN103845731B (zh) * | 2012-12-05 | 2015-12-02 | 复旦大学 | 抗st2/il-1r4抗体在制备防治瘙痒药物中的应用 |
| CN104902925A (zh) * | 2013-01-10 | 2015-09-09 | 诺华股份有限公司 | 流感病毒免疫原性组合物及其应用 |
| WO2014118305A1 (en) | 2013-02-01 | 2014-08-07 | Novartis Ag | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
| EP2769738B1 (en) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 |
| SI3194401T1 (sl) | 2014-09-16 | 2020-12-31 | Gilead Sciences, Inc. | Trdne oblike modulatorja toličnega receptorja |
| EP3061826A1 (en) * | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US11779603B2 (en) | 2016-06-30 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HERV-E reactive T cell receptors and methods of use |
| RU2742337C2 (ru) * | 2016-09-09 | 2021-02-04 | Такеда Фармасьютикал Компани Лимитед | Циклическое соединение |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| CN111447948B (zh) | 2017-12-04 | 2025-09-02 | 英特维特国际股份有限公司 | 具有复制子颗粒和油佐剂的疫苗 |
| US10857153B2 (en) * | 2018-06-04 | 2020-12-08 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| JP7483732B2 (ja) | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| KR20220004637A (ko) * | 2019-04-05 | 2022-01-11 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 수용성 보조제 |
| KR20220025873A (ko) * | 2019-07-03 | 2022-03-03 | 메르크 파텐트 게엠베하 | 당형태 정제 |
| WO2021001387A1 (en) * | 2019-07-03 | 2021-01-07 | Merck Patent Gmbh | Antibody drug conjugate purification |
| US11744874B2 (en) | 2019-12-20 | 2023-09-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
| JP2023507190A (ja) | 2019-12-20 | 2023-02-21 | ノバルティス アーゲー | 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用 |
| US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| US20230321067A1 (en) | 2020-06-23 | 2023-10-12 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7690222B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| AU2022412821A1 (en) * | 2021-12-15 | 2024-08-01 | Innovstone Therapeutics Limited | Aromatic heterocyclic compounds, preparation method therefor and uses thereof |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN119497716A (zh) * | 2023-06-15 | 2025-02-21 | 石药集团中奇制药技术（石家庄）有限公司 | 一种enpp1抑制剂的晶型 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| EP0907738A1 (en) | 1996-04-02 | 1999-04-14 | Smithkline Beecham Corporation | Novel compounds |
| EP0914330A4 (en) | 1996-05-14 | 2002-01-09 | Smithkline Beecham Corp | NEW TYPE COMPOUNDS |
| DK0942983T4 (en) | 1996-10-31 | 2014-12-01 | Human Genome Sciences Inc | Streptococcus pneumoniae antigens and vaccines |
| GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| WO1999010497A1 (en) | 1997-08-21 | 1999-03-04 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Novel mutants of gram negative mucosal bacteria and application thereof in vaccines |
| JPH1180156A (ja) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| ATE476508T1 (de) | 1997-11-06 | 2010-08-15 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| AU1537699A (en) | 1997-11-26 | 1999-06-15 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Extracellular matrix-binding proteins from (staphylococcus aureus) |
| JP4399112B2 (ja) | 1998-01-14 | 2010-01-13 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原 |
| CA2328399A1 (en) | 1998-04-23 | 1999-10-28 | University Of Alabama At Birmingham | Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor |
| EP2261357A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| JP2002531055A (ja) | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
| JP2002521058A (ja) | 1998-07-27 | 2002-07-16 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌由来の核酸及びタンパク質 |
| MXPA01002119A (es) | 1998-08-31 | 2003-03-27 | Inhibitex Inc | Vacunas multicomponentes. |
| EP2311944A1 (en) | 1998-08-31 | 2011-04-20 | The Provost, Fellows and Scholars of the College Of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
| JP2004511201A (ja) | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
| GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| WO2000037105A2 (en) | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| EP1165795A2 (en) | 1999-03-26 | 2002-01-02 | Provalis UK Limited | Streptococcus pneumoniae antigens |
| HK1043943A1 (zh) | 1999-06-10 | 2002-10-04 | Medimmune, Inc. | 肺炎链球菌蛋白质和疫苗 |
| EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
| AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
| US8273360B2 (en) | 2000-01-17 | 2012-09-25 | Novartis Ag | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| ATE352631T1 (de) | 2000-02-28 | 2007-02-15 | Novartis Vaccines & Diagnostic | Heterologe expression von neisseria proteine |
| US20020061569A1 (en) | 2000-03-21 | 2002-05-23 | Robert Haselbeck | Identification of essential genes in prokaryotes |
| EP1278856A2 (en) | 2000-04-27 | 2003-01-29 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| US6495079B1 (en) | 2000-06-28 | 2002-12-17 | Prisma Fibers, Inc. | Process to prepare polymeric fibers with improved color and appearance |
| CA2414884A1 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| US20040091495A1 (en) | 2000-07-20 | 2004-05-13 | Lars Bjorck | Protein |
| BRPI0112928B1 (pt) | 2000-07-27 | 2017-08-29 | Children's Hospital & Research Center At Oakland | A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| EP1330473A2 (en) | 2000-10-26 | 2003-07-30 | Imperial College Innovations Limited | Streptococcal genes |
| EP2277894A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| ATE557041T1 (de) | 2001-05-18 | 2012-05-15 | Us Gov Health & Human Serv | Peptid-vakzinen gegen streptokokken der gruppe a |
| EP2339344A1 (en) | 2001-06-15 | 2011-06-29 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| US7410647B2 (en) | 2001-08-02 | 2008-08-12 | University Of Sheffield | Antigenic polypeptides |
| WO2003049762A2 (en) | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| EP2275122A3 (en) | 2002-04-02 | 2011-05-18 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| ES2285174T3 (es) | 2002-06-11 | 2007-11-16 | Glaxosmithkline Biologicals S.A. | Composiciones inmunogenicas. |
| GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| DK2255826T3 (en) | 2002-08-02 | 2016-06-20 | Glaxosmithkline Biologicals Sa | Neisserial vaccine compositions comprising a combination of antigens. |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| ES2504166T3 (es) | 2002-09-13 | 2014-10-08 | Novartis Vaccines And Diagnostics, Inc. | Vacuna de estreptococo del grupo B |
| EP2353608B1 (en) | 2002-10-11 | 2019-12-18 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| NZ543467A (en) | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
| AU2004230244B2 (en) | 2003-04-15 | 2011-09-22 | Intercell Ag | S. pneumoniae antigens |
| DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| CN1812809A (zh) | 2003-06-26 | 2006-08-02 | 希龙公司 | 用于沙眼衣原体的免疫原性组合物 |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| CA2555342A1 (en) | 2004-02-18 | 2005-09-01 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| EP2893938B1 (en) | 2004-09-22 | 2019-03-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against Staphylococcei |
| ES2616294T3 (es) | 2005-01-27 | 2017-06-12 | Children's Hospital & Research Center At Oakland | Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis |
| JP2009521707A (ja) | 2005-12-27 | 2009-06-04 | オーベテック， エルエルシー | 疾患のバイオマーカーとしての脂肪生成アデノウイルス |
| EP2368570A3 (en) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| US20080031877A1 (en) | 2006-02-17 | 2008-02-07 | Antonello Covacci | Purification of bacterial antigens |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
| EP2476433A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| JP5380465B2 (ja) * | 2008-03-03 | 2014-01-08 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｔｌｒ活性モジュレーターとしての化合物および組成物 |
| AU2010258677B2 (en) * | 2009-06-10 | 2016-10-06 | Glaxosmithkline Biologicals S.A. | Benzonaphthyridine-containing vaccines |
| CN102760226B (zh) * | 2011-04-29 | 2015-07-01 | 贵州师范大学 | 一种基于实心正方形的试卷客观题答题卡定位方法 |
-
2010
- 2010-08-31 TW TW099129346A patent/TWI445708B/zh active
- 2010-08-31 JO JOP/2010/0304A patent/JO3257B1/ar active
- 2010-09-01 HU HUE10807754A patent/HUE032323T2/en unknown
- 2010-09-01 WO PCT/US2010/047587 patent/WO2011049677A1/en not_active Ceased
- 2010-09-01 US US12/874,153 patent/US9045470B2/en active Active
- 2010-09-01 PE PE2012000285A patent/PE20121156A1/es active IP Right Grant
- 2010-09-01 MX MX2012002654A patent/MX2012002654A/es unknown
- 2010-09-01 PT PT108077546T patent/PT2473508T/pt unknown
- 2010-09-01 BR BR112012004696A patent/BR112012004696B8/pt active IP Right Grant
- 2010-09-01 ES ES10807754.6T patent/ES2627669T3/es active Active
- 2010-09-01 AU AU2010308524A patent/AU2010308524B2/en active Active
- 2010-09-01 LT LTEP10807754.6T patent/LT2473508T/lt unknown
- 2010-09-01 EP EP10807754.6A patent/EP2473508B1/en active Active
- 2010-09-01 DK DK10807754.6T patent/DK2473508T3/en active
- 2010-09-01 EA EA201200406A patent/EA020962B1/ru not_active IP Right Cessation
- 2010-09-01 HR HRP20170707TT patent/HRP20170707T1/hr unknown
- 2010-09-01 SI SI201031468A patent/SI2473508T1/sl unknown
- 2010-09-01 SM SM20170276T patent/SMT201700276T1/it unknown
- 2010-09-01 CA CA2772657A patent/CA2772657C/en active Active
- 2010-09-01 JP JP2012528021A patent/JP5525614B2/ja active Active
- 2010-09-01 CN CN201080049422.8A patent/CN102712636B/zh active Active
- 2010-09-01 IN IN2736DEN2012 patent/IN2012DN02736A/en unknown
- 2010-09-01 PL PL10807754T patent/PL2473508T3/pl unknown
- 2010-09-02 AR ARP100103222A patent/AR078153A1/es active IP Right Grant
- 2010-09-02 UY UY0001032874A patent/UY32874A/es unknown
-
2012
- 2012-02-29 CL CL2012000535A patent/CL2012000535A1/es unknown
-
2015
- 2015-04-24 US US14/696,165 patent/US20150225432A1/en not_active Abandoned
-
2017
- 2017-06-08 CY CY20171100605T patent/CY1119618T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000535A1 (es) | Compuestos derivados de benzo[f][1,7]-naftiridina; moduladores de la actividad del receptor tipo-toll 8 (tlr); composicion farmaceutica; utiles para el tratamiento del asma, enfermedad pulmonar obstructiva cronica (copd), sindrome respiratorio de adultos (ards), colitis ulcerosa, enfermedad de crohn, entre otras. | |
| CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
| CL2014001486A1 (es) | Compuestos derivados de urea, inhibidores de quinasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades tales como neumonia eosinofilica cronica, asma, copd, sindrome de angustia respiratoria en adultos (ards), entre otras. | |
| CL2008000307A1 (es) | Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc. | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| IL227990B (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| CL2008003480A1 (es) | Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| CL2012003723A1 (es) | Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida. | |
| CL2007002274A1 (es) | Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras. | |
| CL2007002099A1 (es) | Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma. | |
| ECSP11011163A (es) | Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| EP2847198A4 (en) | TETRAHYDRO [1,8] NAPHTHYRIDINE-SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS MMR AGONISTS AND IN THE TREATMENT OF DISEASE | |
| ECSP12012010A (es) | Nuevos antagonistas del receptor CCR2 y usos de los mismos. | |
| PL3321355T3 (pl) | Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| CL2007003765A1 (es) | Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias. | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
| PE20141012A1 (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion |